You will continue to your video after the current ad
In this episode of Health Insights, Dr. Holly Atkinson sits down with Dr. Harris Foster to discuss overactive bladder including possible symptoms, who is at risk and what to expect after being diagnosed with OAB.
This video features Dr Holly Atkinson. Dr. Holly Atkinson specializes in Internal Medicine and is an award-winning medical journalist. She is also an Assistant Professor in the Department of Preventive Medicine as well as Assistant Clinical Professor in the Department of Medicine at Mt. Sinai Hospital.
Duration: 4:12. Last Updated On: June 2, 2014, 9:50 a.m.
03:07such as in men with an enlarged prostate can give similar symptoms.
03:11>> When you end up with a diagnosis of true OAB,
03:16does that mean we don't know what causes it?
03:19In the absence of some of the other diseases that are very definable,
03:26and you have the symptom of OAB, then the answer is,
03:31we don't know exactly what causes it.
03:33And it may be a process of aging, whereby the nerves are less active.
03:40So that bladder function becomes abnormal,
03:44resulting in the symptoms that we see with OAB.
03:50>> So here's the insight.
03:52Overactive bladder is very common.
03:55Anyone can have the condition, but it does tend to affect older women the most.
03:59If you are experiencing symptoms and haven't been diagnosed, it's important to
04:04see a doctor to determine if you do have OAB, or some other medical condition.
Apostolidis A. Neuromodulation for intractable OAB. Neurourol Urodyn 2011;30(50):766-70.
Athanasopoulos A, Chapple C, Fowler C, Gratzke C, Kaplan S, Stief C, Tubaro A. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011;60(1):94-105. Epub 2011 Apr 9.
Carr LK. Botulinum toxin A should not be first-line therapy for overactive bladder. Can Urol Assoc J 2011;5(3):204-5.
Dmochowski RR, Gomelsky A. Update on the treatment of overactive bladder. Curr Opin Urol 2011;21(4):286-90.
Heidler S, Mert C, Temml C, Madersbacher S. The natural history of the overactive bladder syndrome in females: A long-term analysis of a health screening project. Neurourol Urodyn 2011, Jun 9. [Epub ahead of print]
Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011;30(50):754-7.
Schnitzler A, Genet F, Durand MC, Roche N, Bensmail D, Chartier-Kastler E, Denys P. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: Investigation of generalized spread using single-fiber EMG. Neurourol Urodyn 2011, Jun 9. doi: 10.1002/nau.21103. [Epub ahead of print]
Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65(5):567-85.
Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, Dubeau CE, Lowe FC, Petrou SP, Van Kerrebroeck PE , Rosen RC, Wein AJ. The evaluation and treatment of nocturia: a consensus statement. BJU Int 2011;108(1):6-21.